Treatment-Related Healthcare Costs of Metastatic Castration-Resistant Prostate Cancer in Germany: A Claims Data Study
- Location
-
Deutsche Nationalbibliothek Frankfurt am Main
- ISSN
-
2509-4254
- Extent
-
Online-Ressource
- Language
-
Englisch
- Notes
-
online resource.
- Bibliographic citation
-
Treatment-Related Healthcare Costs of Metastatic Castration-Resistant Prostate Cancer in Germany: A Claims Data Study ; day:30 ; month:5 ; year:2020 ; pages:1-12
PharmacoEconomics - open ; (30.5.2020), 1-12
- Creator
- Contributor
-
SpringerLink (Online service)
- DOI
-
10.1007/s41669-020-00219-6
- URN
-
urn:nbn:de:101:1-2020080221114531531753
- Rights
-
Open Access; Der Zugriff auf das Objekt ist unbeschränkt möglich.
- Last update
-
14.08.2025, 10:55 AM CEST
Data provider
This object is provided by:
Deutsche Nationalbibliothek. If you have any questions about the object, please contact the data provider.
Deutsche Nationalbibliothek. If you have any questions about the object, please contact the data provider.
Associated
- Kreis, Kristine
- Horenkamp-Sonntag, Dirk
- Schneider, Udo
- Zeidler, Jan
- Glaeske, Gerd
- Weissbach, Lothar
- SpringerLink (Online service)
Other Objects (12)
Treatment-Related Healthcare Costs of Metastatic Castration-Resistant Prostate Cancer in Germany: A Claims Data Study
Ureter metastatic castration-resistant prostate cancer: a case report
Physician preferences for non-metastatic castration-resistant prostate cancer treatment
Radioligand therapy of metastatic castration-resistant prostate cancer: current approaches
Chemotherapy management for unfit patients with metastatic castration-resistant prostate cancer
Metastatic Castration-Resistant Prostate Cancer: Advances in Treatment and Symptom Management
Healthcare Costs in Men with Metastatic Castration-Resistant Prostate Cancer: An Analysis of US Medicare Fee-For-Service Claims
Metronomic cyclophosphamide for bone marrow carcinomatosis in metastatic castration-resistant prostate cancer
Navigating therapeutic sequencing in the metastatic castration-resistant prostate cancer patient journey
Correction to: Darolutamide: A Review in Non-Metastatic Castration-Resistant Prostate Cancer
Practical recommendations for radium-223 treatment of metastatic castration-resistant prostate cancer
Drug costs in the management of metastatic castration-resistant prostate cancer in Canada
Treatment-Related Healthcare Costs of Metastatic Castration-Resistant Prostate Cancer in Germany: A Claims Data Study
Ureter metastatic castration-resistant prostate cancer: a case report
Physician preferences for non-metastatic castration-resistant prostate cancer treatment
Radioligand therapy of metastatic castration-resistant prostate cancer: current approaches
Chemotherapy management for unfit patients with metastatic castration-resistant prostate cancer
Metastatic Castration-Resistant Prostate Cancer: Advances in Treatment and Symptom Management
Healthcare Costs in Men with Metastatic Castration-Resistant Prostate Cancer: An Analysis of US Medicare Fee-For-Service Claims
Metronomic cyclophosphamide for bone marrow carcinomatosis in metastatic castration-resistant prostate cancer
Navigating therapeutic sequencing in the metastatic castration-resistant prostate cancer patient journey
Correction to: Darolutamide: A Review in Non-Metastatic Castration-Resistant Prostate Cancer
Practical recommendations for radium-223 treatment of metastatic castration-resistant prostate cancer
Drug costs in the management of metastatic castration-resistant prostate cancer in Canada
Treatment-Related Healthcare Costs of Metastatic Castration-Resistant Prostate Cancer in Germany: A Claims Data Study
Ureter metastatic castration-resistant prostate cancer: a case report
Physician preferences for non-metastatic castration-resistant prostate cancer treatment
Radioligand therapy of metastatic castration-resistant prostate cancer: current approaches
Chemotherapy management for unfit patients with metastatic castration-resistant prostate cancer
Metastatic Castration-Resistant Prostate Cancer: Advances in Treatment and Symptom Management
Healthcare Costs in Men with Metastatic Castration-Resistant Prostate Cancer: An Analysis of US Medicare Fee-For-Service Claims
Metronomic cyclophosphamide for bone marrow carcinomatosis in metastatic castration-resistant prostate cancer
Navigating therapeutic sequencing in the metastatic castration-resistant prostate cancer patient journey
Correction to: Darolutamide: A Review in Non-Metastatic Castration-Resistant Prostate Cancer
Practical recommendations for radium-223 treatment of metastatic castration-resistant prostate cancer